Clinical Pharmacy Practice Department, Faculty of Pharmacy, The British University in Egypt, El-Sherouk City, Cairo 11837, Egypt.
National Cancer Institute, Breast Cancer Hospital, The First Settlement, Cairo, Egypt.
Asian Pac J Cancer Prev. 2024 Oct 1;25(10):3619-3625. doi: 10.31557/APJCP.2024.25.10.3619.
Adjuvant endocrine therapy has been shown to improve treatment outcomes in breast cancer patients. However, not all patients can complete their scheduled treatment protocols. The purpose of this study was to evaluate the adherence to oral hormonal therapy among Egyptian breast cancer patients.
A cross-sectional study was conducted at the National Cancer Institute, Breast Cancer Hospital, from February 2022 to May 2022. An interview and a survey were administered to assess the adherence of breast cancer patients to oral hormonal treatment. Adherence was measured using the Morisky Medication Adherence Scale-8 (MMAS-8).
The survey was fully completed by 300 patients, of whom 98.3% were females and 1.7% were males. Among the patients, 30% fell into the age group of 40-50 years. Most patients were postmenopausal (90.3%). In terms of education, 18% had a high level of education, while 53.3% were illiterate. Additionally, 50.7% of patients had other chronic diseases. Regarding medication information, 44.7% preferred to receive it from a physician, 27.7% from pharmacists, and 27.7% from both. Proper medication counseling was received by 99.7% of patients. According to the MMAS-8 survey, 40.3% of all patients demonstrated high adherence to their oral hormonal treatment, 32.7% had moderate adherence, and 27% had low adherence. No significant associations were found between adherence levels and subgroups such as gender, age, educational level, duration of endocrine therapy, breast cancer stage, or other co-morbidities.
This study reveals a substantial level of adherence, both high and moderate, to oral endocrine therapy among breast cancer patients in Egypt. Possible contributing factors include proper medication counseling within the healthcare setting and regular patient follow-up.
辅助内分泌治疗已被证明能改善乳腺癌患者的治疗效果。然而，并非所有患者都能完成既定的治疗方案。本研究旨在评估埃及乳腺癌患者对口服激素治疗的依从性。
这是一项 2022 年 2 月至 5 月在埃及国家癌症研究所乳腺癌医院进行的横断面研究。通过访谈和问卷调查评估乳腺癌患者对口服激素治疗的依从性。采用 Morisky 药物依从量表-8（MMAS-8）衡量依从性。
共有 300 名患者完成了问卷调查，其中 98.3%为女性，1.7%为男性。患者年龄 40-50 岁的占 30%，绝经后患者占 90.3%。在教育方面，18%的患者受过高等教育，而 53.3%为文盲。此外，50.7%的患者患有其他慢性疾病。在用药信息方面，44.7%的患者更喜欢从医生那里获取信息，27.7%的患者更喜欢从药剂师那里获取信息，27.7%的患者更喜欢从两者那里获取信息。99.7%的患者接受了适当的用药指导。根据 MMAS-8 调查，所有患者中，40.3%高度依从口服激素治疗，32.7%中度依从，27%低度依从。依从水平与性别、年龄、教育水平、内分泌治疗持续时间、乳腺癌分期或其他合并症等亚组之间无显著关联。
本研究表明，埃及乳腺癌患者对口服内分泌治疗具有较高和中等水平的依从性。可能的促成因素包括在医疗保健环境中提供适当的用药指导和定期的患者随访。
